Pfizer enters development accord for Adolor's delta-opioid blockers

World drug giant Pfizer and USA-based Adolor have entered an exclusive worldwide collaboration to develop and commercialize two novel compounds, ADL5859 and ADL5747, for the treatment of pain. Both agents are proprietary delta-opioid receptor agonist candidates with the potential to treat a wide range of inflammatory, neuropathic and acute pain conditions. Under the terms of the deal, the firms will share US revenues and expenses at 60% and 40%, respectively. Outside the domestic market, Pfizer will fund development activities and, on commercialization, Adolor will receive royalties on net sales, as well as an upfront, non-refundable payment of $30.0 million, plus $1.9 million reimbursement for prior Phase